A-83-01, an inhibitor of TGF-β type I receptor, increased the expression of Myf5 and MyoD, and enhanced myotube formation.The targeting efficacy of single intravenous injections of F-SL combined with A-83-01 was evaluated by measurement of the biodistribution and the antitumor effect in mice bearing murine lung carcinoma M109. A-83-01 temporarily changed the tumor vasculature around 3 h post injection. A-83-01 induced 1.7-fold higher compound accumulation of F-SL in the tumor than liposome alone at 24 h post injection.
*The compound is unstable in solutions, freshly prepared is recommended
Biochim Biophys Acta Gen Subj. 2024 Jan;1868(4):130566.
Gastric cancer patient-derived organoids model for the therapeutic drug screening
A 83-01 purchased from AbMole
Adv Sci (Weinh). 2023 Jul 23;e2302640.
Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients
A 83-01 purchased from AbMole
Cell Death Dis. 2022 Apr 5;13(4):303.
KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response
A 83-01 purchased from AbMole
Nat Biomed Eng. 2020 Sep;4(9):863-874.
High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays
A 83-01 purchased from AbMole
Molecular Weight | 421.52 |
Formula | C25H19N5S |
CAS Number | 909910-43-6 |
Solubility (25°C) | DMSO 24 mg/mL |
Storage | -20°C, protect from light, dry, sealed |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related TGF-β Receptor Products |
---|
LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. |
LSKL, Inhibitor of Thrombospondin (TSP-1)
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. |
KRFK
KRFK, a peptide derived from TSP-1, can activate TGF-β. |
Maohuoside A
Maohuoside A potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways |
Vicatertide
Vicatertide is a TGF beta-1 inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.